Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Average Target Price from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $10.00.

A number of research analysts have recently commented on the company. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. Royal Bank of Canada lifted their target price on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Stephens assumed coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. StemPoint Capital LP acquired a new position in Pyxis Oncology in the first quarter valued at approximately $7,643,000. Ikarian Capital LLC acquired a new position in shares of Pyxis Oncology in the 1st quarter valued at $7,082,000. Vanguard Group Inc. boosted its position in shares of Pyxis Oncology by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after purchasing an additional 94,740 shares during the last quarter. Millennium Management LLC grew its stake in shares of Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after purchasing an additional 743,499 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after purchasing an additional 57,016 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.90 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a market capitalization of $112.99 million, a PE ratio of -1.84 and a beta of 1.27. The business’s 50-day simple moving average is $3.64 and its 200-day simple moving average is $3.62.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.